Video Interview: Placental Stem Therapy Offers 'Off The Shelf' Promise
This article was originally published in Scrip
Pluristem Therapeutics chair and CEO Zami Aberman explains to Mike Ward, global director of content for Informa Pharma Insights how stem cell therapy will shape the industry. Using placental cells and a proprietary, three-dimensional (3D) technology platform, Pluristem is developing "off the shelf" cell therapies for a broad spectrum of diseases. Pluristem converts human placental stem cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. The company's pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. Aberman tells Mike Ward that his company intends to use the $17m it raised in 2015 to complete current clinical studies and start new ones.